SynCore Biotechnology Co.,Ltd (TPEX:4192)
18.85
0.00 (0.00%)
Sep 14, 2026, 1:33 PM CST
TPEX:4192 Revenue
SynCore Biotechnology Co.,Ltd had revenue of 6.28M TWD in the quarter ending June 30, 2026, a decrease of -19.70%. This brings the company's revenue in the last twelve months to 26.24M, up 4.63% year-over-year. In the year 2025, SynCore Biotechnology Co.,Ltd had annual revenue of 27.04M with 15.88% growth.
Revenue (ttm)
26.24M
Revenue Growth
+4.63%
P/S Ratio
25.26
Revenue / Employee
655.98K
Employees
40
Market Cap
662.86M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 27.04M | 3.71M | 15.88% |
| Dec 31, 2024 | 23.34M | 3.14M | 15.55% |
| Dec 31, 2023 | 20.20M | 4.34M | 27.36% |
| Dec 31, 2022 | 15.86M | 8.92M | 128.52% |
| Dec 31, 2021 | 6.94M | -6.40M | -47.97% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Meribank Biotech | 408.48M |
| Taiwan Advance Bio-Pharmaceutical | 348.54M |
| BioLASCO Taiwan | 258.04M |
| TCI GENE | 251.39M |
| Lukas Biomedical | 170.01M |
| Vectorite Biomedical | 54.81M |
| Enimmune | 53.45M |
| Neith | 31.84M |